Clinical Trial Update: A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model [Phase 2]

View source ↗

Summary

This update reports results from a controlled Phase 2a trial evaluating EDP-323 for respiratory syncytial virus infection in a virus challenge model.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• EDP-323 (EDP-323)

Snippet

Sponsor: Enanta Pharmaceuticals, Inc | Conditions: RSV Infection | Phase 2 | Status: COMPLETED | Results posted: 2025-10-07